Real-World data reveals how schizophrenia patients actually use new drug KarXT
NCT ID NCT07571148
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This study looks at health records and insurance claims from nearly 7,000 adults in the U.S. who are taking KarXT for schizophrenia. Researchers want to understand who gets the drug, how it's prescribed, and how often people need hospital visits or other care. The goal is to see how KarXT works in real life, not just in controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Veradigm
Chicago, Illinois, 60654, United States
Conditions
Explore the condition pages connected to this study.